IN2013MN01107A - - Google Patents

Download PDF

Info

Publication number
IN2013MN01107A
IN2013MN01107A IN1107MUN2013A IN2013MN01107A IN 2013MN01107 A IN2013MN01107 A IN 2013MN01107A IN 1107MUN2013 A IN1107MUN2013 A IN 1107MUN2013A IN 2013MN01107 A IN2013MN01107 A IN 2013MN01107A
Authority
IN
India
Prior art keywords
compounds
general formula
relates
cancer
prostate cancer
Prior art date
Application number
Other languages
English (en)
Inventor
Ian Weeks
Mohammed Jaffar
Richard Knox
Original Assignee
Univ Cardiff
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Cardiff filed Critical Univ Cardiff
Publication of IN2013MN01107A publication Critical patent/IN2013MN01107A/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57434Specifically defined cancers of prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/04Nitro compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • A61K31/122Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/366Lactones having six-membered rings, e.g. delta-lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • C12Q1/32Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving dehydrogenase
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/902Oxidoreductases (1.)
    • G01N2333/90209Oxidoreductases (1.) acting on NADH or NADPH (1.6), e.g. those with a heme protein as acceptor (1.6.2) (general), Cytochrome-b5 reductase (1.6.2.2) or NADPH-cytochrome P450 reductase (1.6.2.4)
IN1107MUN2013 2010-12-20 2011-12-08 IN2013MN01107A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1021494.8A GB201021494D0 (en) 2010-12-20 2010-12-20 Compounds
PCT/GB2011/052430 WO2012085532A2 (en) 2010-12-20 2011-12-08 Methods and compounds for detecting cancer

Publications (1)

Publication Number Publication Date
IN2013MN01107A true IN2013MN01107A (es) 2015-06-12

Family

ID=43598602

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1107MUN2013 IN2013MN01107A (es) 2010-12-20 2011-12-08

Country Status (12)

Country Link
US (1) US20140370520A1 (es)
EP (1) EP2655653B1 (es)
CN (1) CN103492586A (es)
AU (1) AU2011346906B2 (es)
BR (1) BR112013015394A2 (es)
CA (1) CA2822369A1 (es)
DK (1) DK2655653T3 (es)
ES (1) ES2563097T3 (es)
GB (1) GB201021494D0 (es)
HK (1) HK1191062A1 (es)
IN (1) IN2013MN01107A (es)
WO (1) WO2012085532A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201810152T4 (tr) 2011-10-14 2018-08-27 The Board Of Regents Of The Universty Of Texas System Bileşikler ve anti-tümör nqo1 substratları.

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1551841A1 (en) * 2002-07-23 2005-07-13 SmithKline Beecham Corporation Pyrazolopyrimidines as kinase inhibitors
DE10303265A1 (de) * 2003-01-28 2004-07-29 Roche Diagnostics Gmbh Fluorimetrische Bestimmung von Analyten durch ein intramolekulares Quencher-Fluorophor-Konjugat
CN101384255A (zh) * 2006-02-09 2009-03-11 癌症治疗公司 使用e09和丙二醇治疗膀胱癌
US20090012031A1 (en) * 2007-07-03 2009-01-08 The Regents Of The University Of Michigan EZH2 Cancer Markers
TWI354101B (en) * 2008-08-19 2011-12-11 Univ Nat Taipei Technology Fluorimetric indicator for biosensing and manufact
WO2011113018A1 (en) * 2010-03-12 2011-09-15 Ampere Life Sciences, Inc. Measurement and control of biological time

Also Published As

Publication number Publication date
US20140370520A1 (en) 2014-12-18
WO2012085532A3 (en) 2012-08-16
AU2011346906B2 (en) 2016-03-03
WO2012085532A2 (en) 2012-06-28
BR112013015394A2 (pt) 2016-09-20
ES2563097T3 (es) 2016-03-10
GB201021494D0 (en) 2011-02-02
CA2822369A1 (en) 2012-06-28
CN103492586A (zh) 2014-01-01
HK1191062A1 (zh) 2014-07-18
EP2655653B1 (en) 2015-11-18
EP2655653A2 (en) 2013-10-30
DK2655653T3 (da) 2016-02-22
AU2011346906A1 (en) 2013-07-04

Similar Documents

Publication Publication Date Title
MX341133B (es) Compuestos y metodos para la inhibición de hdac.
MX341456B (es) Amino-quinolinas como inhibidores de cinasa.
PH12014502697A1 (en) New diazaspirocycloalkane and azaspirocycloalkane
IN2015DN00960A (es)
IN2012DN02751A (es)
MY169043A (en) New dihydroquinoline-2-one derivatives
MX2014014531A (es) Derivados de aminoquinazolina y piridopirimidina.
MX2012008141A (es) Compuestos y metodos.
EP2566477A4 (en) AMINO-QUINOLINES AS KINASE INHIBITORS
MX2014001879A (es) Aminoquinazolinas como inhibidores de quinasa.
EA201170154A1 (ru) Производные пиридинопиридинонов, способ их получения и применение в терапии
PH12015500345A1 (en) Amino-quinolines as kinase inhibitors
MY169267A (en) New aryl-quinoline derivatives
IN2012DN01342A (es)
MX339300B (es) Inhibidores de molecula pequeña de la activacion n-terminal del receptor de androgenos.
TN2013000354A1 (en) Synthesis of 2-carboxamide cycloamino urea derivatives
HK1124842A1 (en) Methods of preparing imidazole-based compounds
IN2012DN05081A (es)
MX2012007835A (es) Derivados de oxazolopirimidina sustituida en 2, 5,7.
MX2012005155A (es) Compuestos de quinazolina.
MX2013009388A (es) Nuevos compuestos de azaespirodecanona como inhibidores de lipasa sensible a hormonas (hsl).
IN2013MN01107A (es)
UA34487U (en) Aquananomagnesium
GB2501403A (en) 3-Arylethynyl substituted quinazolinone compounds
MX344429B (es) Nuevos compuestos de hexahidropirroloimidazolona.